Intermittent dysphagia in a causal smoker.
Explore the source record for details and available documents.
Aged↗
Biomedical subjects
L D Joyce
Publications and source records attributed to L D Joyce.
Establishing and using a local/regional cardiac surgery database.
BACKGROUND: In 1993, the Minnesota Society of Thoracic Surgeons and the Minnesota Cardiac Surgery Database were organized in response to a third-party payer demand for data about practice protocols and patient outcomes. It has matured to an active organization of 46 cardiothoracic surgeons, 14 institutions, and more than 7,000 patients who have undergone coronary artery bypass grafting. METHODS: Data are validated for completeness and accuracy through a statewide auditing process. They are coded by hospital, analyzed using the standard Society of Thoracic Surgeons National Cardiac Surgery Database format and definitions, and reviewed quarterly in a continuous quality improvement process. RESULTS: Through data review and exchange site visits, variations in practice protocols and outcomes have been identified. For example, our statewide data review and continuous quality improvement process identified prolonged ventilation (more than 24 hours) as one variation. Multidisciplinary teams were defined, and statewide exchange site visits led by cardiovascular surgeons were implemented. An example of the improvement in the accuracy and completeness of the data used to study procedure outcomes is represented by the improved reporting of ejection fraction values that has resulted from this process. CONCLUSIONS: Using the standardized Society of Thoracic Surgeons National Cardiac Surgery Database and the Minnesota Society of Thoracic Surgeons organizational structure to establish a high-quality database will allow for statewide peer review, exchange of practice guidelines, and promotion of standardization, which eventually can improve outcomes and reduce costs. This organization or model can be replicated at any local, state, or regional level. Thoracic surgeons faced with similar challenges for public disclosure of surgical results can learn much from the successful development of the Minnesota Cardiac Surgery Database.
Clinical Protocols↗
Experience with generally accepted centrifugal pumps: personal and collective experience.
BACKGROUND: The data presented are a brief summary of The International Registry for Mechanical Ventricular Assist Pumps and Artificial Hearts and a summary of the personal experience of the Minnesota Thoracic Associates at the Minneapolis Heart Institute with the use of the Sams centrifugal pump from May 1985 to September 1994. METHODS: Ventricular support with the use of centrifugal pumps for postcardiotomy shock consisted of cannulation of the left atrium and aorta for left ventricular support and the right atrium and pulmonary artery for right ventricular support, or the combination of the two for biventricular support. RESULTS: The average survival and discharge rate recorded by the National Registry for postcardiotomy syndrome was 25.3%. Our experience at Minnesota Thoracic Associates was 54%. The National Registry reported 45.7% of the patients being weaned from the device or receiving transplants and 25.3% of the patients ultimately discharged from the hospital. Sixty-five percent of the patients in our experience either were weaned from the device or received a transplant for an overall discharge rate of 42%. The average effective hospital cost per survivor was almost $400,000.00. CONCLUSIONS: It is our belief that when considering the cost analysis of temporary devices, one must conclude that a more economical approach for the treatment of end-stage cardiac disease would be aggressive development of a permanent ventricular assist device.
Cardiac Surgical Procedures↗
North American experience with the Perma-Flow prosthetic coronary graft.
BACKGROUND: The Perma-Flow prosthetic coronary graft is a 5-mm polytetrafluoroethylene tube into which is incorporated a Venturi flow restrictor. An aorto-superior vena caval fistula is created and coronary anastomoses are constructed proximal to the resistor in side-to-side fashion, where arterial pressure is maintained. From November 1992 through December 1995, eight investigational centers in North America have implanted this graft in 40 patients with inadequate autologous alternatives. METHODS: Patients were selected for inclusion in this study if coronary artery bypass grafting was required and adequate autologous conduit to complete revascularization was not available. Operative data were completed by the implantating surgeon and referred to a central center, the Minneapolis Heart Institute, for correlation. Follow-up was conducted by data coordinators at each institution, and follow-up data were obtained directly from these coordinators for inclusion in the study. RESULTS: Patient age ranged from 53 to 82 years, and 15 patients were undergoing reoperations (38%). On each Perma-Flow graft one to four coronary side-to-side anastomoses were constructed. In addition, left internal mammary artery (n = 26), greater saphenous vein (8), right internal mammary artery (4), and gastroepiploic artery (4) were used to complete revascularization. Aortic (2) or mitral valve replacement (1) was also carried out. There were seven operative deaths (18%) and two late deaths (4 and 6 months). After 1 to 37 months (mean, 13 +/- 9 months) of follow-up, 29 of 31 surviving patients are asymptomatic. Echocardiographic heart size has not increased from the postoperative value, indicating limited volume load has not affected heart size. Protocol catheterization (n = 32) in 28 patients 1 week to 1 year postoperatively revealed 7 of 73 studied coronary anastomoses (9.5%) and two distal extensions and resistors were occluded (7%). In 1 patient during sternal debridement at 1 year, no flow was found in the graft. CONCLUSIONS: The Perma-Flow graft is a useful adjunct to complete revascularization in patients with deficient autologous conduit.
Aged↗
Acquired coarctation of the descending thoracic aorta.
Explore the source record for details and available documents.
Adult↗
Operative considerations in implantation of the Perma-Flow graft.
The Perma-Flow coronary bypass graft (Possis Medical, Inc, Minneapolis, MN) currently is undergoing expanded clinical trial. From November 1992 through June 1994 we have used this artificial conduit in 8 patients without autologous alternatives. These cases allowed the establishment of a technical basis for successful implantation of this graft. All studied coronary anastomoses are patent.
Aorta↗
Nonpulsatile circulatory support: techniques of insertion.
Explore the source record for details and available documents.
Aged↗
Experience with the symbion total artificial heart as a bridge to transplantation.
From December 1985 through January 1991, 9 patients underwent bridging to transplantation using a Symbion J-7-70 total artificial heart. There were 4 female and 5 male patients aged 31 +/- 14 years (range, 15 to 52 years). Five patients were supported on an intraaortic balloon pump before total artificial heart support, and 2 had biventricular assist devices as well. Total artificial heart support was maintained for 17 +/- 12 days (range, 4 to 44 days); all patients underwent transplantation. Three patients died after transplantation on day 0 (primary donor organ failure), 25 (acute rejection), and 256 (multiorgan failure). The remainder were discharged at 41 +/- 32 days (range, 13 to 101 days). One patient died 28 months after transplantation of late acute rejection. Actuarial 1-year and 3-year survival is 67% and 55%. There were no surgical wound infections. Problems encountered in the J-7-70 period and the period after transplantation were for the most part related to patient condition in the period before implantation. The Symbion J-7-70 total artificial heart is an effective device for total circulatory support in patients with end-stage cardiogenic shock when an organ donor is not available. Organ system failure and infection before implantation may persist into the transplantation period resulting in long-term complications, increased mortality, and prolonged hospital stay; therefore, early implantation of the device when indicated should be applied.
Adolescent↗
Mechanical circulatory assistance after heart transplantation.
From October 1985 through December 1989, 92 heart transplant procedures were performed in 89 patients. Nine patients (aged 19 to 66 years; 7 male, 2 female) required mechanical circulatory support after transplantation because of primary idiopathic organ failure (n = 2), implant difficulty (2), poor organ quality (2), or acute right heart failure (3). Devices used included the intraaortic balloon pump (6), centrifugal right ventricular assist device (2), left ventricular assist (1), biventricular assists (2), and total artificial heart (1). Two patients required multiple devices. One patient underwent retransplantation. Implant time ranged from 1 to 18 days. One early death occurred owing to right heart failure 6 days after transplantation, 7 hours after removal of a right ventricular assist device, for an overall mortality of 11%. The remaining 8 patients are alive 4 months to 28 months after transplantation. The actuarial 1-year survival of 89% +/- 10% compares well with the survival of 87% +/- 4% for the entire transplant group. All surviving patients are in functional class I. Echocardiographic examination in all patients revealed left ventricular ejection fraction to be normal in 7 and depressed in 1. Extending the criteria for organ donors or difficulty with the implant procedure can lead to early organ failure, which may be reversible with circulatory assistance allowing excellent survival.
Adult↗
Directions in cardiac assistance.
The use of mechanical circulatory support devices came to prominence with the use of the Jarvik 7 total artificial heart, both as a permanent implant and as a bridge to transplantation. Over the past decade, however, interest in the use of left ventricular assist devices has overshadowed that of the total artificial heart and great strides have been made, both in the use of such devices as temporary support, and towards the ultimate goal of permanent implantation. A variety of devices are available to support either or both ventricles with a great range of complexity and expense. This test discusses the use of ventricular assist devices and briefly describes the options available. The era is rapidly approaching when the use of implantable circulatory support devices will become commonplace and may outpace, and possibly outperform, the results currently obtained with cardiac transplantation.
Cardiac Output, Low↗
Emergency cardiopulmonary bypass support in patients with cardiac arrest.
Emergency percutaneous cardiopulmonary bypass support was instituted in 11 patients in cardiac arrest refractory to conventional resuscitation measures. Emergency percutaneous cardiopulmonary bypass support was used in five patients in whom cardiac arrest occurred as a result of a complication in the cardiac catheterization laboratory (group 1) and in six other patients in cardiac arrest (group II). A 21F cannula and a 17F cannula were percutaneously inserted into the femoral vein and artery. Flow rates of 3 to 5 L/min were achieved with restoration of mean arterial pressure to 70 mm Hg (range 50 to 75). The status of all 11 patients was improved initially both clinically and hemodynamically with percutaneous cardiopulmonary bypass. Of the group II patients, three had anatomy unsuitable for percutaneous transluminal coronary angioplasty or coronary bypass grafting, could not be weaned from cardiopulmonary support, and died; three of these patients had coronary artery bypass grafting and two survived. All five group I patients underwent successful coronary bypass grafting and survived. Of the seven patients with anatomically correctable disease, all seven were discharged from the hospital. With conventional management nearly all seven of these patients would have died. Nine of 11 patients underwent a cardiac operation and seven of the nine survived. The operative mortality rate was 22% and the overall survival rate was 64%. At follow-up (mean 7 months), all seven patients are alive and six have resumed a normal and active life-style. In conclusion, emergency percutaneous cardiopulmonary bypass support is a powerful resuscitative tool that may stabilize the condition of patients in cardiogenic shock and cardiac arrest to allow for definitive intervention.
Cardiac Catheterization↗
Circulatory Support 1988. Patient selection.
Explore the source record for details and available documents.
Assisted Circulation↗
Results of the first 100 patients who received Symbion Total Artificial Hearts as a bridge to cardiac transplantation.
Between August 8, 1985 and April 1, 1988, 100 patients in 22 centers underwent Symbion Total Artificial Heart (TAH) (Symbion, Inc., Salt Lake City, Utah) implantation as a bridge to cardiac transplant. Thirty patients received the Symbion J7-100, and 70 patients received Symbion J7-70 implants. Eighty-seven patients were men and 13 were women; mean age was 42 years, and mean weight was 73 kg. The time spent on the device ranged from 1 to 243 days, for a mean of 23 days. Sixty-eight patients underwent cardiac transplantation, with a 69% 30-day survival rate and a 46% (31 of 68) long-term survival rate. The majority of the patients had ischemic (52) or idiopathic (36) cardiomyopathies. Indications for implantation of the TAH occurred most frequently in patients whose condition deteriorated while awaiting transplant (34) or who were admitted in acute cardiogenic shock (27). There was an 8.7% incidence of thromboembolic events (four cerebrovascular accidents, five transient ischemic attacks). Multivariant analysis was performed to determine the effect of various factors on the patients' ability to undergo transplantation and then ultimate survival. The results indicate a need for further clinical investigation in patient selection and appropriate timing for implantation of the TAH.
Adult↗
Mechanical circulatory support as a bridge to transplantation.
From December 1985 through April 1988, 11 patients (three female and eight males), 33.1 +/- 3.9 (+/- SEM) years of age (range, 15 to 50 years), underwent heart transplantation preceded by the use of mechanical circulatory support. The causes of cardiac failure were ischemic (four), viral cardiomyopathy (three), idiopathic cardiomyopathy (two), congenital heart disease (one), and valvular heart disease (one). All patients were preterminal. Mechanical circulatory support consisted of intra-aortic balloon pump (eight), the total artificial heart (seven), biventricular assist (three), and left ventricular assist (two). Seven patients had more than one form of support. The duration of mechanical circulatory support was 12.2 +/- 4.1 days (range, 1 to 44 days). Once listed for transplantation, patients waited for 8.1 +/- 2.4 days for a donor. Seven patients received OKT3 monoclonal antibody as prophylaxis, in addition to triple-drug immunosuppression. There were four rejection episodes and 12 serious infections. In addition, eight patients suffered a major posttransplant complication of a distant organ system: central nervous system (three), renal (two), and respiratory (three). Post transplant hospitalization was 48 +/- 22 days (range, 15 to 248 days). Two patients (18%) died after transplant, one of severe acute rejection (29 days) and one of multisystem failure (248 days). All patients surviving transplant hospitalization are alive 6 to 34 months after the transplant procedure. Eight patients are in functional class I and 1 patient class II. This patient attends school full-time but has a premechanical support system neurologic defect. In follow-up of 163 patient-months except for yearly catheterization, these nine patients required only 5 hospital days. Although the use of the mechanical circulatory support as a bridge to transplantation can result in a prolonged, complicated hospitalization after transplant, the long-term results are gratifying.
Adolescent↗
Infectious complications in four long-term recipients of the Jarvik-7 artificial heart.
This article describes the infectious complications that occurred among four of the longest-term recipients of the Jarvik-7 artificial heart. Infection arising from the drive lines, with spread to the mediastinal periprosthetic space, was the major limiting factor in long-term use of the device in these patients. Periprosthetic infections were due to coagulase-negative staphylococci, Staphylococcus aureus, Pseudomonas aeruginosa, and other Pseudomonas species. Other infectious complications incurred by some of the patients included pneumonia, empyema, urinary tract infection, and intravascular line sepsis with Candida. Intensive antimicrobial therapy for prolonged periods seemed to suppress but not to eradicate infection and was accompanied by the appearance of multiresistant bacterial strains. Complications of antimicrobial therapy included diarrhea secondary to overgrowth with Clostridium difficile in two patients. Use of the current device for more than 30 days should be considered extraordinary and should be reserved for patients for whom no other form of life support is available.
Adult↗
Ganciclovir pharmacokinetics during renal impairment.
Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.
Acyclovir↗
Evaluation of total artificial heart performance in man.
This report describes the method whereby total artificial heart (TAH) performance was evaluated in the first human implantation, the operating characteristics of the TAH and the accompanying circulatory response. The patient survived for 112 days. Weekly averages (+/- standard deviation) for left-heart drive pressure ranged from 146 +/- 5 to 171 +/- 10 mm Hg, right-heart drive pressure from 46 +/- 4 to 79 +/- 17 mm Hg, heart rate from 77 +/- 8 to 98 +/- 3 beats/min, diastolic vacuum from 0 to 7 +/- 0.5 mm Hg and percent systole 40 +/- 1 to 44 +/- 0. Left-sided cardiac output ranged from 3.0 +/- 0.4 to 3.9 +/- 0.2 liters/min/m2, and was consistently greater than right-sided cardiac output, which ranged from 2.6 +/- 0.4 to 3.6 +/- 0.1 liters/min/m2. Drive line air pressure and flow signals and cineradiography of the TAH demonstrated complete filling and ejection for the left ventricle and complete filling but partial ejection for the right ventricle. There was no significant change in cardiac index during variation in right atrial pressure between 4 and 14 mm Hg. During 21 days of invasive hemodynamic monitoring, daily average of mean systemic arterial pressure ranged from 81 +/- 5 to 107 +/- 11 mm Hg, pulmonary artery pressure from 22 +/- 2 to 28 +/- 8 mm Hg and left atrial pressure from 8 +/- 2 to 22 +/- 4 mm Hg. Prominent V waves on the left atrial pressure tracing suggested mitral regurgitation as a cause of the difference between the outputs of the 2 ventricles.(ABSTRACT TRUNCATED AT 250 WORDS)
Air Pressure↗
Clinical use of the total artificial heart.
We report here our first experience with the use of a total artificial heart in a human being. The heart was developed at the University of Utah, and the patient was a 61-year-old man with chronic congestive heart failure due to primary cardiomyopathy, who also had chronic obstructive pulmonary disease. Except for dysfunction of the prosthetic mitral valve, which required replacement of the left-heart prosthesis on the 13th postoperative day, the artificial heart functioned well for the entire postoperative course of 112 days. The mean blood pressure was 84 +/- 8 mm Hg, and cardiac output was generally maintained at 6.7 +/- 0.8 liters per minute for the right heart and 7.5 +/- 0.8 for the left, resulting in postoperative diuresis and relief of congestive failure. The postoperative course was complicated by recurrent pulmonary insufficiency, several episodes of acute renal failure, episodes of fever of unidentified cause (necessitating multiple courses of antibiotics), hemorrhagic complications of anticoagulation, and one generalized seizure of uncertain cause. On the 92nd postoperative day, the patient had diarrhea and vomiting, leading to aspiration pneumonia and sepsis. Death occurred on the 112th day, preceded by progressive renal failure and refractory hypotension, despite maintenance of cardiac output. Autopsy revealed extensive pseudomembranous colitis, acute tubular necrosis, peritoneal and pleural effusion, centrilobular emphysema, and chronic bronchitis with fibrosis and bronchiectasis. The artificial heart system was intact and uninvolved by thrombosis or infectious processes. This experience should encourage further clinical trials with the artificial heart, but we emphasize that the procedure is still highly experimental. Further experience, development, and discussion will be required before more general application of the device can be recommended.
Blood Pressure↗